Beth Israel Deaconess Medical Center donations received

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donee information

ItemValue
Country
Wikipedia pagehttps://en.wikipedia.org/wiki/Beth_Israel_Deaconess_Medical_Center

Donee donation statistics

Cause areaCountMedianMeanMinimum10th percentile 20th percentile 30th percentile 40th percentile 50th percentile 60th percentile 70th percentile 80th percentile 90th percentile Maximum
Overall 17 1,063,805 4,614,330 -3,350,000 0 0 110,716 594,199 1,063,805 4,084,674 4,999,946 9,285,024 18,031,416 20,000,356
Global health 16 1,010,000 4,719,326 -3,350,000 0 0 100,000 594,199 1,010,000 4,084,674 8,848,220 9,285,024 18,031,416 20,000,356
Scientific research 1 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400 2,934,400

Donation amounts by donor and year for donee Beth Israel Deaconess Medical Center

Donor Total 2018 2017 2016 2015 2014 2013 2012 2011 2006
Bill and Melinda Gates Foundation (filter this donee) 75,509,216.21 0.00 4,084,674.00 -455,137.79 1,649,946.00 20,000,356.00 2,073,805.00 9,285,024.00 20,839,133.00 18,031,416.00
Open Philanthropy (filter this donee) 2,934,400.00 2,934,400.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total 78,443,616.21 2,934,400.00 4,084,674.00 -455,137.79 1,649,946.00 20,000,356.00 2,073,805.00 9,285,024.00 20,839,133.00 18,031,416.00

Full list of documents in reverse chronological order (1 documents)

Title (URL linked)Publication dateAuthorPublisherAffected donorsAffected doneesAffected influencersDocument scopeCause areaNotes
This Powerhouse Funder is Still New to Scientific Research. Where Are Grants Going?2018-04-17Paul Karon Inside PhilanthropyOpen Philanthropy MIT Synthetic Neurobiology Group Beth Israel Deaconess Medical Center University of Washington (Institute for Protein Design) Third-party coverage of donor strategyScientific researchThe article discusses grantmaking by the Open Philanthropy Project in the domain of scientific research, noting that the grants were often made in areas overlapping with other interests (such as global health). The large donation to the Institute for Protein Design in connection with influenza research is highlighted.

Full list of donations in reverse chronological order (17 donations)

Graph of top 10 donors (for donations with known year of donation) by amount, showing the timeframe of donations

Graph of donations and their timeframes
DonorAmount (current USD)Amount rank (out of 17)Donation dateCause areaURLInfluencerNotes
Open Philanthropy2,934,400.0082018-01Scientific researchhttps://www.openphilanthropy.org/focus/scientific-research/miscellaneous/beth-israel-deaconess-medical-center-clinical-trial-sepsis-therapyChris Somerville Heather Youngs Grant to support Dr. Michael Donnino to conduct a multicenter clinical trial of a therapy for severe sepsis. Announced: 2018-01-30.
Bill and Melinda Gates Foundation4,084,674.0072017-05-22Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop HIV-1 Env based vaccine candidates capable of inducing neutralizing antibodies.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation594,199.00112016-11-15Global health/Tuberculosis controlhttps://iatiregistry.org/publisher/bmgf-- to determine the capacity of antibodies to protect against naturally-transmitted Mycobacterium tuberculosis (Mtb); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-799,336.79162016-08-02Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-250,000.00152016-04-27Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-3,350,000.00172015-10-02Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop a novel vector/protein HIV-1 Env vaccine for the developing world. Development of Novel Vector/Protein HIV-1 Vaccines. Investment start date: 9/6/2012 to end date: 12/31/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation4,999,946.0062015-10-02Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to evaluate whether a combination of ART and bNab treatment in HIV-infected individuals could potentially contribute to prolonged and/or lifelong treatment interruption; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation20,000,356.0012014-07-18Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to evaluate whether a combination of ART and bNab treatment in HIV-infected individuals could potentially contribute to prolonged and/or lifelong treatment interruption; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation1,010,000.00102013-06-03Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation1,063,805.0092013-04-02Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to generate and to evaluate a clade C SHIV challenge stock. Production of Clade C SHIV Stock. Investment start date: 4/2/2013 to end date: 4/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation110,716.00122013-03-06Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop a novel HIV-1 RV144-like vaccine regimen using an improved vaccine vector Mycobacterium bovis Bacillus Calmette-Guerin; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation-110,716.00142013-03-06Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation9,285,024.0042012-09-06Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop a novel vector/protein HIV-1 Env vaccine for the developing world. Development of Novel Vector/Protein HIV-1 Vaccines. Investment start date: 9/6/2012 to end date: 12/31/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation11,890,913.0032011-11-10Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation8,848,220.0052011-10-21Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop a novel HIV-1 RV144-like vaccine regimen using an improved vaccine vector Mycobacterium bovis Bacillus Calmette-Guerin; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
Bill and Melinda Gates Foundation100,000.00132011-04-20Global health/malariahttps://iatiregistry.org/publisher/bmgf-- to develop a cell phone compatible diagnostic screening device based solely on the principles of magnetic levitation, allowing detection of malaria-infected red blood cells.; Aid type: Project-type interventions. Affected regions: South of Sahara.
Bill and Melinda Gates Foundation18,031,416.0022006-06-21Global health/STD control including HIV/AIDShttps://iatiregistry.org/publisher/bmgf-- to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.